Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment

Ann Rheum Dis. 2015 Dec;74(12):2261-4. doi: 10.1136/annrheumdis-2015-207978. Epub 2015 Oct 6.

¹ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan.
² Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
³ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
⁴ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.

No abstract available

Keywords: Ankylosing Spondylitis; Anti-TNF; Rheumatoid Arthritis.

Publication types